Medullary Thyroid Cancer (MTC) Completed Phase 1 Trials for Trastuzumab (DB00072)

Back to Medullary Thyroid Cancer (MTC)

Also known as: Thyroid Carcinoma, Medullary / Medullary carcinoma of thyroid / Thyroid Gland Medullary Carcinoma / Thyroid Medullary Carcinoma / Thyroid Cancer, Medullary / Medullary Thyroid Carcinoma / Medullary Thyroid Cancer / Medullary thyroid carcinoma (disorder) / Medullary carcinoma with amyloid stroma (morphologic abnormality) / Parafollicular cell carcinoma (disorder) / Medullary thyroid carcinoma (morphologic abnormality) / C cell neuroendocrine neoplasm / Parafollicular cell carcinoma / C cell carcinoma / Ultimobranchial thyroid tumor / Ultimobranchial thyroid tumour / MTC - Medullary thyroid carcinoma / Medullary carcinoma with amyloid stroma -RETIRED-

Indication	Status	Phase
DBCOND0062236 (Medullary Thyroid Cancer (MTC))	Completed	1

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT00004074	Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu	Treatment	Carboplatin (DB00958) Edodekin alfa (DB15631) Natural Killer Cell (DB15721) Paclitaxel (DB01229) Trastuzumab (DB00072)